Showing 2881-2890 of 4166 results for "".
- Sight Sciences Announces Positive Clinical Results From Trial Evaluating TearCare for the Treatment of Dry Eye Diseasehttps://modernod.com/news/sight-sciences-announces-positive-clinical-results-from-trial-evaluating-tearcare-for-the-treatment-of-dry-eye-disease/2477787/Sight Sciences announced new dry eye clinical data from a multicenter trial of TearCare, the first wearable eyelid technology for dry eye. Data from the study were presented at the American Society of Cataract Refractive Surgery (ASCRS) Virtual annual meeting by Jennifer Loh, MD, practicing ophth
- RegeneRx Joint Venture Announces Efficacy Results of Neurotrophic Keratopathy Phase 3 Clinical Trial with RGN-259https://modernod.com/news/regenerx-joint-venture-announces-efficacy-results-of-neurotrophic-keratopathy-phase-3-clinical-trial-with-rgn-259/2477764/ReGenTree LLC, a US joint venture company owned by GtreeBNT Co. and RegeneRx Biopharmaceuticals, announced the results of a randomized, double masked, placebo-controlled phase 3 clinical trial (SEER-1) using RGN-259 for the treatment of neurotrophic keratopathy (NK).
- Ocular Therapeutix Announces First Patient Dosed in Phase 1 Clinical Trial of OTX-CSI For Treatment of Dry Eye Diseasehttps://modernod.com/news/ocular-therapeutix-announces-first-patient-dosed-in-phase-1-clinical-trial-of-otx-csi-for-treatment-of-dry-eye-disease/2477754/Ocular Therapeutix announced that it has dosed the first patients in its phase 1 clinical trial of OTX-CSI (cyclosporine intracanalicular insert) for the treatment of dry eye disease (DED). “We are pleased to be advancing OTX-CSI in the chronic treatment of dry eye disease,” Michael Goldst
- Ocular Therapeutix Announces Topline Results of Phase 3 Clinical Trial of Dextenza for Allergic Conjunctivitishttps://modernod.com/news/ocular-therapeutix-announces-topline-results-of-phase-3-clinical-trial-of-dextenza-for-allergic-conjunctivitis/2477659/Ocular Therapeutix announced topline results from its phase 3 clinical trial to evaluate the safety and efficacy of Dextenza for the treatment of ocular itching associated with allergic conjunctivitis (AC). In the phase 3 trial, Dextenza met all prespecified primary endpoints as demonstrated by a
- WHO Accidently Leaks Disappointing Results of Chinese Clinical Trial Testing Gilead’s Remdesivir in Severe COVID-19https://modernod.com/news/who-accidently-leaks-disappointing-results-of-chinese-clinical-trial-testing-gileads-remdesivir-in-severe-covid-19/2477645/According to a draft document published in error by the World Health Organization (WHO), Gilead Sciences’ remdesivir failed to improve the condition of patients with severe COVID-19 participating in a Chinese clinical trial, nor was the drug found to reduce the virus’ presence in the
- Inovio Initiates Phase 1 Clinical Trial Of Its COVID-19 Vaccine and Plans First Dose Todayhttps://modernod.com/news/inovio-initiates-phase-1-clinical-trial-of-its-covid-19-vaccine-and-plans-first-dose-today/2477532/Inovio Pharmaceuticals announced that the FDA has accepted the company’s investigational new drug (IND) application for INO-4800, its DNA vaccine candidate designed to prevent COVID-19 infection, paving the way for phase 1 clinical testing of INO-4800 in healthy volunteers beginning this we
- COVID-19 Roundtable: How Retina Doctors From Around the United States Are Adjusting Their Clinicshttps://modernod.com/news/covid-19-roundtable-how-retina-doctors-from-around-the-united-states-are-adjusting-their-clinics/2477467/Eyewire News checked in with four retina specialists in COVID-19 hotspots around the United States—Seattle, New York, Boston, and Orlando—to see how they are adjusting their clinics in light of the AAO’s latest guidance. To read a full summary of their adjustments, read the forthcoming April issu
- FDA Approves Genentech’s Clinical Trial for Actemra to Treat Hospitalized Patients With Severe COVID-19 Pneumoniahttps://modernod.com/news/fda-approves-genentechs-clinical-trial-for-actemra-to-treat-hospitalized-patients-with-severe-covid-19-pneumonia/2477442/Genentech announced Monday that the FDA has approved a randomized, double-blind, placebo-controlled phase 3 clinical trial in collaboration with the Biomedical Advanced Research and Development Authority (BARDA) to evaluate the safety and efficacy of intravenous Actemra (tocilizumab) plus standar
- Palatin Technologies Announces First Patient Enrolled in Dry Eye Disease Phase 2 Clinical Trial With PL9643https://modernod.com/news/palatin-technologies-announces-first-patient-enrolled-in-dry-eye-disease-phase-2-clinical-trial-with-pl9643/2477303/Palatin Technologies announced that it has enrolled the first patient in a phase 2 clinical trial of topical PL9643, a melanocortin 1/5 receptor (MC1/5r) agonist, for the treatment of dry eye disease (DED). “We are pleased to initiate this phase 2 study of PL9643 exploring treatment
- Acucela Provides Update on Emixustat Phase 3 Clinical Trial in Patients with Stargardt Diseasehttps://modernod.com/news/acucela-provides-update-on-emixustat-phase-3-clinical-trial-in-patients-with-stargardt-disease/2477295/Acucela announced that the company has achieved over 65% subject enrollment in its ongoing phase 3 clinical trial investigating emixustat hydrochloride in patients with macular atrophy secondary to Stargardt disease. The study is a multicenter, randomized, double-masked, and placebo-contro